<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31520" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Calcium Carbonate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fritz</surname>
            <given-names>Kristina</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Taylor</surname>
            <given-names>Katherine</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristina Fritz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Katherine Taylor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31520.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Calcium carbonate is an inorganic salt primarily used to manage and treat low calcium conditions, GERD, CKD, and other indicated conditions. Calcium carbonate is classified as a calcium supplement, antacid, and phosphate binder. This activity outlines the significant indications, actions, and contraindications for calcium carbonate as a valuable agent in treating osteoporosis, hypothyroidism, rheumatoid arthritis, and many other conditions or disorders that lower serum calcium levels.&#x000a0;As an antacid, calcium carbonate also increases gastrointestinal motility and initiates peristalsis. Calcium carbonate works in the small intestines as&#x000a0;a phosphate binder and drug chelator.&#x000a0;In individuals with hyperphosphatemia or overdose, calcium will bind to form an insoluble compound blocking dietary phosphate or excess drug absorption and excreting it in feces.&#x000a0;Calcium carbonate, used as a calcium supplement, also acts in the small intestine by chelating with oxalate to prevent absorption and renal calculi formation.&#x000a0;Lastly, calcium carbonate also works in the blood to treat or prevent negative calcium balance seen in low serum calcium conditions.&#x000a0;This activity will highlight the mechanism of action, adverse event profile, and other key factors (eg, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the care of patients with low serum calcium, GERD, CKD, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for calcium carbonate use in patients with low calcium levels, GERD, CKD, and related conditions.</p></list-item><list-item><p>Screen patients for contraindications and potential drug interactions before initiating calcium carbonate therapy.</p></list-item><list-item><p>Assess patients regularly for response to calcium carbonate therapy, monitor calcium levels, and evaluate for adverse effects.</p></list-item><list-item><p>Communicate effectively with patients about the benefits, risks, and proper use of calcium carbonate.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31520&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31520">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31520.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Calcium carbonate, chemically CaCO<sub>3</sub>, is a resonance-stabilized inorganic salt therapeutically used as a food additive, a dietary supplement, an antacid, and a phosphate binder. Calcium carbonate is among the most abundant compounds found in the earth's crust and is commonly found in organic substances, such as egg and oyster shells, crustaceans exoskeletons, and dark leafy greens, such as broccoli and kale.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref> Calcium carbonate uses extend beyond medicine. Calcium carbonate has industrial uses as filler in paint, paper, fire extinguishers, and adhesives, as a component of agricultural and mining dust, as an ingredient in household cleaners, as a food coloring compound, and as an ingredient in cosmetics.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref></p>
        <p>In pharmaceuticals, calcium carbonate is a food additive used for nutritional benefits, is a calcium supplement used to treat low serum calcium conditions, is an antacid for gastrointestinal ailments, is a phosphate binder for chronic kidney disease, and is a tableting excipient used in the making of other pharmaceutical agents and foodstuffs.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref><xref ref-type="bibr" rid="article-31520.r2">[2]</xref></p>
        <p>Calcium carbonate is indicated for low serum calcium conditions, such as osteoporosis, osteomalacia, hypothyroidism, hypoparathyroidism, pseudohypoparathyroidism, DiGeorge syndrome, kidney dysfunction, pancreatitis, rheumatoid arthritis, Fanconi syndrome, pregnancy, nursing mothers, post-menopausal women, and while using certain medications.<xref ref-type="bibr" rid="article-31520.r3">[3]</xref><xref ref-type="bibr" rid="article-31520.r4">[4]</xref><xref ref-type="bibr" rid="article-31520.r5">[5]</xref><xref ref-type="bibr" rid="article-31520.r6">[6]</xref><xref ref-type="bibr" rid="article-31520.r7">[7]</xref>&#x000a0;The medications that require concurrent calcium supplement use include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Rifampin (antibiotic)</p>
          </list-item>
          <list-item>
            <p>Loop-diuretics</p>
          </list-item>
          <list-item>
            <p>Anti-seizure medications (phenytoin and phenobarbital)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bisphosphonates (alendronate, ibandronate, zoledronic acid, and risedronate)</p>
          </list-item>
          <list-item>
            <p>Calcitonin</p>
          </list-item>
          <list-item>
            <p>Chloroquine</p>
          </list-item>
          <list-item>
            <p>Corticosteroids</p>
          </list-item>
          <list-item>
            <p>Plicamycin</p>
          </list-item>
          <list-item>
            <p>Citrate use during apheresis (anticoagulant)&#x000a0;<xref ref-type="bibr" rid="article-31520.r8">[8]</xref><xref ref-type="bibr" rid="article-31520.r9">[9]</xref><xref ref-type="bibr" rid="article-31520.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>As an antacid, calcium carbonate is indicated for heartburn caused by gastroesophageal reflux disease (GERD), NSAID upper gastrointestinal mucosal damage, duodenal and gastric ulcers, biliary reflux, stress gastritis exocrine pancreatic insufficiency, bile acid-mediated diarrhea, Non-ulcer dyspepsia, and urinary alkalization.<xref ref-type="bibr" rid="article-31520.r11">[11]</xref><xref ref-type="bibr" rid="article-31520.r12">[12]</xref><xref ref-type="bibr" rid="article-31520.r13">[13]</xref>&#x000a0;Like aluminum and magnesium salts, calcium carbonate increases gut motility and has indications for constipation treatment.<xref ref-type="bibr" rid="article-31520.r14">[14]</xref></p>
        <p>Calcium carbonate is also indicated for use in treating hyperphosphatemia seen in chronic kidney disease, as a phosphate binder, as a way of treating overdose by causing urinary alkalization, and as a prophylactic treatment in pregnant patients before birth to prevent aspiration pneumonitis.<xref ref-type="bibr" rid="article-31520.r15">[15]</xref><xref ref-type="bibr" rid="article-31520.r16">[16]</xref></p>
        <p>New research suggests that the indications for calcium carbonate may also include cancer treatment by using calcium supplements to treat colorectal adenomas and using rare-earth-doped calcium carbonate with cerium to kill tumor cells via X-ray-induced photodynamic therapy.<xref ref-type="bibr" rid="article-31520.r17">[17]</xref><xref ref-type="bibr" rid="article-31520.r18">[18]</xref></p>
      </sec>
      <sec id="article-31520.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Calcium is naturally present in the body. Most of the body's stored calcium is within the bones and teeth as hydroxyapatite. The rest of the body's calcium is in blood, extracellular fluid, muscle, and other body tissues.<xref ref-type="bibr" rid="article-31520.r19">[19]</xref> In the blood, 40% of calcium is bound to albumin, 13% binds to an anion, like phosphate and lactate, and the majority, 47%, is free, unbound, ionized calcium (Ca<sup>2+</sup>).&#x000a0;The amount of ionized calcium found in the blood is essential and tightly regulated by homeostatic controls because it is physiologically active and plays a vital role in the cellular processes of excitable tissues, such as blood vessels, muscles, glands, and nerves.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref></p>
        <p>Calcium carbonate has three separate mechanisms of action that have pharmacologic effects. Calcium affects the stomach, small intestine, and blood.<xref ref-type="bibr" rid="article-31520.r20">[20]</xref></p>
        <p>As an antacid, calcium carbonate neutralizes gastric acid by acting as a buffer in the stomach's acidic environment. When CaCO<sub>3</sub> enters the stomach, it dissociates into ionized calcium (Ca<sup>2+</sup>) and a carbonate anion (CO<sub>3</sub><sup>2-</sup>). The carbonate anion will then bind to the free protons (H+) found in the stomach to increase the pH by decreasing the concentration of hydrogen ions. By increasing the pH in the stomach, pepsin, bile acids, and the toxins of&#x000a0;<italic toggle="yes">Helicobacter pylori</italic>&#x000a0;become inhibited.<xref ref-type="bibr" rid="article-31520.r21">[21]</xref></p>
        <p>The inhibition of pepsin, an enzyme that can degrade tissue protein, and inhibition of bile acid helps reduce damage to and promote the healing of ulcers in the mucosal lining of the stomach and duodenum and injury to the esophagus caused by GERD.<xref ref-type="bibr" rid="article-31520.r21">[21]</xref> There is still some criticism regarding the ulcer-healing effects of calcium carbonate solely being due to its acid-neutralizing mechanism because calcium carbonate can cause acid rebound by increasing plasma gastrin levels and has been shown to increase prostaglandins PGE2 and PGF2 after long-term use that may explain an alternative mechanism to ulcer healing.<xref ref-type="bibr" rid="article-31520.r22">[22]</xref><xref ref-type="bibr" rid="article-31520.r23">[23]</xref><xref ref-type="bibr" rid="article-31520.r24">[24]</xref></p>
        <p>As an antacid, calcium carbonate also increases gastrointestinal motility and initiates peristalsis.<xref ref-type="bibr" rid="article-31520.r14">[14]</xref><xref ref-type="bibr" rid="article-31520.r25">[25]</xref>&#x000a0;When the calcium carbonate is chewed and partially digested, the free calcium stimulates peristalsis in the esophagus to move the acid into the stomach and decrease heartburn symptoms.<xref ref-type="bibr" rid="article-31520.r25">[25]</xref>&#x000a0; &#x000a0;</p>
        <p>Calcium carbonate works in the small intestines as a phosphate binder and drug chelator. In individuals with hyperphosphatemia or overdose, calcium will bind to form an insoluble compound blocking dietary phosphate or excess drug absorption and excreting it in feces.&#x000a0;Additionally, calcium carbonate, used as a calcium supplement, also acts in the small intestine by chelating with oxalate to prevent absorption and renal calculi formation.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref></p>
        <p>Lastly, calcium carbonate also works in the blood to treat or prevent negative calcium balance seen in low serum calcium conditions.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref> After being absorbed in the small intestines actively with the help of vitamin D and passively vi-a diffusion, ionized calcium circulates in the blood.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption</bold>: After ingesting calcium carbonate tablets, they are broken down in the stomach to form soluble calcium salts. As a result, calcium becomes available for absorption in the body.&#x000a0;Calcium absorption occurs&#x000a0;in the small intestine by active transport dependent on Vitamin D and diffusion.&#x000a0;Fractional calcium absorption, the amount of calcium absorbed over the amount ingested, changes throughout life and is highest in infancy, early puberty, and the last two trimesters of pregnancy for women. It steadily declines as an individual progresses into old age, with a marked decrease starting after menopause for women and late '50s for men.<xref ref-type="bibr" rid="article-31520.r19">[19]</xref>&#x000a0;Besides age and the form of calcium carbonate, calcium absorption can be affected by the dose given, stomach pH, estrogen status, vitamin D level, and genetic polymorphisms.<xref ref-type="bibr" rid="article-31520.r11">[11]</xref>&#x000a0;</p>
        <p>The fractional absorption is highest at 500 mg when taken with food, and the stomach is acidic.&#x000a0;Fractional absorption also increases when the person has sufficient vitamin D, does not have an absorption disorder, is young, has more estrogen, and has a larger body size.<xref ref-type="bibr" rid="article-31520.r26">[26]</xref>&#x000a0;Absorption of calcium carbonate decreases if an individual has a mucosal lining disorder or achlorhydria.<xref ref-type="bibr" rid="article-31520.r27">[27]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;As previously mentioned, calcium storage in the body is primarily in bones and teeth. However, most of the calcium is found in the ionized, physiologically active form in the blood.&#x000a0;</p>
        <p><bold>Elimination:&#x000a0;</bold>Calcium carbonate is excreted in the feces as unabsorbed calcium carbonate, in the urine depending on glomerular filtration and renal tubule reabsorption controlled by parathyroid hormone (PTH) and Vitamin D, and as carbon dioxide from the lungs.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref></p>
      </sec>
      <sec id="article-31520.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Calcium carbonate comes in tablet, chewable, oral suspension, or powder form. Tablets should be swallowed while drinking a full glass of water. The oral suspension should be well shaken before measuring the dose to ensure the ingestion of the proper amount. The bioavailability of calcium from calcium carbonate is higher as a powder.<xref ref-type="bibr" rid="article-31520.r28">[28]</xref> Although calcium citrate has a higher bioavailability of calcium than calcium carbonate, in foods fortified with calcium, calcium carbonate allows for better absorption than other calcium-fortification compounds.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref><xref ref-type="bibr" rid="article-31520.r29">[29]</xref>&#x000a0;1000 mg&#x000a0;of calcium carbonate is equivalent to 400 mg of elemental calcium.</p>
        <list list-type="bullet">
          <list-item>
            <p>Dosing depends on the indicated condition and the patient's age. For adult use for heartburn, dosing ranges from 500 mg to 1000 mg and should not exceed 7 grams daily.</p>
          </list-item>
          <list-item>
            <p>RDI of Calcium for adults is 1 to 1.2 gm daily, and for post-menopausal women, 1.2 gm preferably from dietary sources. For calcium supplementation,&#x000a0;500 mg to 4 grams of calcium carbonate may be taken orally daily, divided, and with meals.</p>
          </list-item>
          <list-item>
            <p>For adults with hyperphosphatemia, 1.5 to 3 grams per day effectively achieves optimal phosphate control in 65% of patients.<xref ref-type="bibr" rid="article-31520.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>If the patient misses a regular dose, they should take it when they remember it unless it is close to the next dose. At the time of the next dose, they should take the regular dose and not double it.</p>
        <p>Beyond age and form of calcium carbonate, calcium absorption can be affected by the dose given, stomach pH, patient size, estrogen status, vitamin D level, and genetic polymorphisms.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref><xref ref-type="bibr" rid="article-31520.r11">[11]</xref>&#x000a0;When taken with food, the fractional absorption is highest at 500 mg, and the stomach is acidic.&#x000a0;Fractional absorption also increases when the person has sufficient vitamin D, does not have an absorption disorder, is young, has more estrogen, and has a larger body size.<xref ref-type="bibr" rid="article-31520.r31">[31]</xref>&#x000a0;Absorption of calcium carbonate decreases if an individual has a mucosal lining disorder or achlorhydria.<xref ref-type="bibr" rid="article-31520.r27">[27]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic Impairment:&#x000a0;</bold>The&#x000a0;product labeling for calcium carbonate does not include any dosage adjustments for hepatic impairment.</p>
        <p><bold>Renal Impairment: </bold>As per the KDIGO guidelines for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), it is recommended to monitor serum levels of calcium, phosphate, parathyroid hormone, and alkaline phosphatase beginning in CKD G3a (eGFR: 45-59 mL/min/1.73 m&#x000b2;) for adults and in CKD G2 (eGFR: 60-89 mL/min/1.73 m&#x000b2;) for children. For adults with CKD G3a((eGFR: 45 mL/min/1.73 m&#x000b2; or less)-G5D, the guidelines suggest avoiding hypercalcemia. Similarly, in children with CKD G3a-G5D, maintaining serum calcium within the age-appropriate normal range is advised. CKD G5D indicates End-Stage Renal Disease (ESRD), where the eGFR is 15 mL/min/1.73 m&#x000b2; or less and typically necessitates renal replacement therapy, such as dialysis or kidney transplantation.&#x000a0;<bold>&#x000a0;</bold></p>
        <p><bold>Pregnancy Considerations: </bold>Calcium carbonate is for aspiration prophylaxis before labor.<xref ref-type="bibr" rid="article-31520.r2">[2]</xref><xref ref-type="bibr" rid="article-31520.r12">[12]</xref>&#x000a0;GERD occurs in up to 80% of pregnant women by the end of the third trimester. According to the American College of Gastroenterology (ACG) guidelines, treatment typically starts with lifestyle adjustments. Antacids, including calcium carbonate, are the first-line options if these don't suffice. Calcium carbonate is considered safe, effectively neutralizes stomach acid, and provides relief from heartburn and acid indigestion without significant risk to the fetus. However, at high doses, antacids containing calcium can cause milk-alkali syndrome.<xref ref-type="bibr" rid="article-31520.r32">[32]</xref></p>
        <p><bold>Breastfeeding Considerations:&#x000a0;</bold>Calcium can travel through the placenta and into breast milk during nursing.&#x000a0;However, it is unlikely that the additional intake of these minerals by a nursing mother will exceed what is found in other infant foods. Considering these factors, experts generally deem antacids such as calcium carbonate used during breastfeeding acceptable. No specific precautions are necessary in this regard.<xref ref-type="bibr" rid="article-31520.r33">[33]</xref></p>
      </sec>
      <sec id="article-31520.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Due to the short-term, periodic nature of calcium carbonate/antacid use and the small dose of calcium carbonate used for supplementation, most adverse effects are minor. However, an overdose can occur if large doses are taken for an extended time or abused. The patient can experience moderate to severe side effects of an overdose.<xref ref-type="bibr" rid="article-31520.r34">[34]</xref>&#x000a0;These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Irregular heart rhythms</p>
          </list-item>
          <list-item>
            <p>Muscle twitching</p>
          </list-item>
          <list-item>
            <p>Bone pain</p>
          </list-item>
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Pancreatitis<xref ref-type="bibr" rid="article-31520.r35">[35]</xref><xref ref-type="bibr" rid="article-31520.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Acute renal failure</p>
          </list-item>
          <list-item>
            <p>Kidney stones<xref ref-type="bibr" rid="article-31520.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Milk-alkali syndrome<xref ref-type="bibr" rid="article-31520.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Gall stones<xref ref-type="bibr" rid="article-31520.r38">[38]</xref></p>
          </list-item>
        </list>
        <p>Milk-alkali syndrome was historically a much more common severe side effect.&#x000a0;Milk-alkali syndrome results from hypercalciuria and alkaluria, predisposing renal calculi and causing sequelae such as pancreatitis and acute renal failure.<xref ref-type="bibr" rid="article-31520.r39">[39]</xref>&#x000a0;</p>
        <p>Common Adverse Effects:</p>
        <list list-type="bullet">
          <list-item>
            <p>High calcium levels</p>
          </list-item>
          <list-item>
            <p>Low phosphate levels</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Gas</p>
          </list-item>
          <list-item>
            <p>Loss of appetite&#x000a0;or anorexia</p>
          </list-item>
          <list-item>
            <p>Irritability</p>
          </list-item>
          <list-item>
            <p>Xerostomia</p>
          </list-item>
          <list-item>
            <p>Acid rebound&#x000a0;<xref ref-type="bibr" rid="article-31520.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Additional adverse effects occur in individuals taking calcium carbonate as a phosphate binder to treat hyperphosphatemia, including calcification of vascular tissues and death.<xref ref-type="bibr" rid="article-31520.r30">[30]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Calcium carbonate should be stored at room temperature and not frozen or exposed to heat.<xref ref-type="bibr" rid="article-31520.r12">[12]</xref> Calcium carbonate should not be administered with other drugs known to decrease its absorption, such as histamine-2 receptor antagonists, glucocorticoids, and thiazide diuretics, but rather rescheduled to be taken at separate times.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref><xref ref-type="bibr" rid="article-31520.r40">[40]</xref>&#x000a0;Conversely, vitamin D will increase the absorption of calcium carbonate if coadministered, and patients are encouraged to take it together.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref><xref ref-type="bibr" rid="article-31520.r26">[26]</xref></p>
        <p>Additionally, calcium carbonate will limit many drugs' effectiveness if taken together by increasing stomach pH and decreasing absorption.<xref ref-type="bibr" rid="article-31520.r11">[11]</xref> These drugs include bisphosphonates, fluoroquinolones, tetracyclines, thyroid hormones, proton pump inhibitors such as omeprazole, iron, and anti-arrhythmic drugs like verapamil.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref><xref ref-type="bibr" rid="article-31520.r11">[11]</xref><xref ref-type="bibr" rid="article-31520.r41">[41]</xref>&#x000a0;Calcium carbonate can also interact with the excretion of many drugs as it causes urine alkalization and will quicken the excretion of drugs that exist as weak acids and lengthen the excretion of drugs that exist as weak bases in the blood.<xref ref-type="bibr" rid="article-31520.r11">[11]</xref></p>
      </sec>
      <sec id="article-31520.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Calcium carbonate use is contraindicated in hypersensitivity, renal calculus, high urine calcium levels, elevated serum calcium, low serum phosphate, achlorhydria, or suspected digoxin toxicity.</p>
        <p>Care is necessary for patients with a history of kidney disease, heart failure, edema, or endocrine disorders, such as hypoparathyroidism.<xref ref-type="bibr" rid="article-31520.r42">[42]</xref><xref ref-type="bibr" rid="article-31520.r43">[43]</xref>&#x000a0;Additionally, calcium carbonate users should never be prescribed ceftriaxone as an antibiotic because of the increased risk of end-organ failure and death.<xref ref-type="bibr" rid="article-31520.r44">[44]</xref></p>
      </sec>
      <sec id="article-31520.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Adult patients using calcium carbonate as a supplemental therapy should have their serum phosphate and calcium levels periodically monitored to prevent adverse reactions and electrolyte imbalances. If patients continually return to using calcium carbonate, their symptoms require investigation to determine the root cause. Importantly, any patients using calcium carbonate for any reason should never be prescribed ceftriaxone to prevent end-organ failure.<xref ref-type="bibr" rid="article-31520.r44">[44]</xref>&#x000a0;</p>
        <p>Administration of calcium carbonate should be separated from the administration of all medications that have drug interactions mentioned above, apart from vitamin D. Patients with hyperphosphatemia should have their serum calcium routinely monitored to prevent hypercalcemia and other sequelae, including myocardial infarction, vascular calcification, and death.</p>
        <p>Pediatric and&#x000a0;older patients should be routinely monitored if using calcium carbonate and advised against long-term use.</p>
      </sec>
      <sec id="article-31520.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The FDA recognizes calcium carbonate as a generally safe drug and food additive.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref> A maximum dose of 8 to 10 g per day of calcium carbonate can be administered for short-term use.<xref ref-type="bibr" rid="article-31520.r2">[2]</xref><xref ref-type="bibr" rid="article-31520.r45">[45]</xref>&#x000a0;However, long-term use of over 2 grams can lead to adverse effects such as hypercalcemia, renal calculi, hypophosphatemia, and nephrotoxicity, especially in individuals with chronic kidney disease.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref><xref ref-type="bibr" rid="article-31520.r11">[11]</xref>&#x000a0;Fetotoxicity has also been observed in pregnant women taking over 1500 mg/kg of body weight per day of calcium carbonate.<xref ref-type="bibr" rid="article-31520.r1">[1]</xref></p>
      </sec>
      <sec id="article-31520.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As a non-prescription drug, calcium carbonate is easily accessible "over the counter" and often used. Proper patient education by clinicians and pharmacists is needed to avoid improper use. Symptomatic relief provided by calcium carbonate often masks underlying gastrointestinal disorders that will not improve by using the drug. Patient awareness is necessary to hasten the correct diagnosis and treatment. Furthermore, patients on polypharmacy need to understand calcium carbonate's drug interactions. Clinicians should advise their patients to take their medications at separate times of the day and limit additional calcium intake that could lead to overdose and milk-alkali syndrome. Working with a pharmacist to assist with medication reconciliation would be a prudent choice to prevent adverse drug-drug interactions. Nurses can also work with the patient to answer questions, review appropriate dosing, and ensure patient compliance. These are examples of how interprofessional teamwork and communication can improve patient results with calcium carbonate therapy, respective of the reason the patient takes it.</p>
        <p>Proper clinician education on considerations when prescribing, monitoring, and stopping treatment is also necessary.&#x000a0;Vigilance&#x000a0;is essential, and routine monitoring should occur when prescribing calcium carbonate to patients with hyperphosphatemia due to the possibility of calcification of vascular tissues. Care is also necessary when prescribing calcium carbonate to infants and older patients because of renal function changes. Additionally, calcium carbonate should not be coadministered with ceftriaxone because of an increased risk of end-organ failure.&#x000a0;</p>
        <p>All interprofessional&#x000a0;healthcare team members can improve outcomes by ensuring patient compliance. Patient compliance is problematic with calcium carbonate because of its interactions, adverse effects, and frequency of administration. Calcium carbonate can be inconvenient because it must be taken alone, except for vitamin D and other drugs that do not require a low stomach pH. Calcium carbonate has many gastrointestinal side effects, especially for older adults. Calcium carbonate prescriptions can also translate to a high pill burden, like patients with hyperphosphatemia who may require more than 17 doses daily. Encouraging patient compliance and proper scheduling would greatly help improve patients on polypharmacy, those with comorbidities, and those who need to limit dietary electrolytes.</p>
      </sec>
      <sec id="article-31520.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31520&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31520">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31520/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31520">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31520.s11">
        <title>References</title>
        <ref id="article-31520.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Omari</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Qinna</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Jaber</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Badwan</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Calcium Carbonate.</article-title>
            <source>Profiles Drug Subst Excip Relat Methodol</source>
            <year>2016</year>
            <volume>41</volume>
            <fpage>31</fpage>
            <page-range>31-132</page-range>
            <pub-id pub-id-type="pmid">26940168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Salisbury</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Antacids</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30252305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karatzas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paridis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kozyrakis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tzortzis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Samarinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dailiana</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Karachalios</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fanconi syndrome in the adulthood. The role of early diagnosis and treatment.</article-title>
            <source>J Musculoskelet Neuronal Interact</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>303</fpage>
            <page-range>303-306</page-range>
            <pub-id pub-id-type="pmid">29199190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Cusano</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Mannstadt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rejnmark</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rizzoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Liberman</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Potts</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Management of Hypoparathyroidism: Present and Future.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>101</volume>
            <issue>6</issue>
            <fpage>2313</fpage>
            <page-range>2313-24</page-range>
            <pub-id pub-id-type="pmid">26938200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jorde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Szumlas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haug</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sundsfjord</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake.</article-title>
            <source>Eur J Nutr</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>258</fpage>
            <page-range>258-63</page-range>
            <pub-id pub-id-type="pmid">12474069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.</article-title>
            <source>Nutrients</source>
            <year>2017</year>
            <month>Apr</month>
            <day>26</day>
            <volume>9</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">28445420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Farr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bold</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Serum calcium levels in rheumatoid arthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1981</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>580</fpage>
            <page-range>580-3</page-range>
            <pub-id pub-id-type="pmid">7332378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Blackwell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Ensrud</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2009</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>855</fpage>
            <page-range>855-62</page-range>
            <pub-id pub-id-type="pmid">19368583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulation techniques in apheresis: from heparin to citrate and beyond.</article-title>
            <source>J Clin Apher</source>
            <year>2012</year>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>117</fpage>
            <page-range>117-25</page-range>
            <pub-id pub-id-type="pmid">22532037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckley</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Leib</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Cartularo</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Vacek</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Ann Intern Med</source>
            <year>1996</year>
            <month>Dec</month>
            <day>15</day>
            <volume>125</volume>
            <issue>12</issue>
            <fpage>961</fpage>
            <page-range>961-8</page-range>
            <pub-id pub-id-type="pmid">8967706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maton</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>855</fpage>
            <page-range>855-70</page-range>
            <pub-id pub-id-type="pmid">10400401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Da&#x0011f;l&#x00131;</surname>
                <given-names>&#x000dc;</given-names>
              </name>
              <name>
                <surname>Kalkan</surname>
                <given-names>&#x00130;H</given-names>
              </name>
            </person-group>
            <article-title>Treatment of reflux disease during pregnancy and lactation.</article-title>
            <source>Turk J Gastroenterol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>Suppl 1</issue>
            <fpage>S53</fpage>
            <page-range>S53-S56</page-range>
            <pub-id pub-id-type="pmid">29199169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ching</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Antacids. Indications and limitations.</article-title>
            <source>Drugs</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>305</fpage>
            <page-range>305-17</page-range>
            <pub-id pub-id-type="pmid">7512903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matzkies</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Webs</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>[The effect of 4 different antacids on the gastrointestinal tract and mineral metabolism].</article-title>
            <source>Fortschr Med</source>
            <year>1984</year>
            <month>Jun</month>
            <day>28</day>
            <volume>102</volume>
            <issue>24</issue>
            <fpage>661</fpage>
            <page-range>661-5</page-range>
            <pub-id pub-id-type="pmid">6469178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Battistella</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New agent to treat elevated phosphate levels: magnesium carbonate/calcium carbonate tablets.</article-title>
            <source>CANNT J</source>
            <year>2012</year>
            <season>Oct-Dec</season>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>33</fpage>
            <page-range>33-5; quiz 36-7</page-range>
            <pub-id pub-id-type="pmid">23413537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Mudge</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Pillans</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Phosphate binders in patients with chronic kidney disease.</article-title>
            <source>Aust Prescr</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-14</page-range>
            <pub-id pub-id-type="pmid">28246429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Rare-Earth-Doped Calcium Carbonate Exposed to X-ray Irradiation to Induce Reactive Oxygen Species for Tumor Treatment.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Mar</month>
            <day>06</day>
            <volume>20</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">30845750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Hussey</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Alberts</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Meyskens</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Fenoglio-Preiser</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rivkin</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Giguere</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Blanke</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions.</article-title>
            <source>Clin Colorectal Cancer</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>310</fpage>
            <page-range>310-6</page-range>
            <pub-id pub-id-type="pmid">21782524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <collab>Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes</collab>
            <source>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</source>
            <publisher-name>National Academies Press (US)</publisher-name>
            <publisher-loc>Washington (DC)</publisher-loc>
            <year>1997</year>
            <pub-id pub-id-type="pmid">23115811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biandrate</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piccolini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Francia</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Oncocytoma of the kidney: a diagnostic and therapeutic dilemma].</article-title>
            <source>Minerva Chir</source>
            <year>1989</year>
            <month>Oct</month>
            <day>15</day>
            <volume>44</volume>
            <issue>19</issue>
            <fpage>2113</fpage>
            <page-range>2113-8</page-range>
            <pub-id pub-id-type="pmid">2694016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarnawski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids.</article-title>
            <source>Curr Pharm Des</source>
            <year>2013</year>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <page-range>126-32</page-range>
            <pub-id pub-id-type="pmid">22950493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berstad</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berstad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acute effects of antacids on gastric juice components in duodenal ulcer patients.</article-title>
            <source>Eur J Clin Invest</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>511</fpage>
            <page-range>511-5</page-range>
            <pub-id pub-id-type="pmid">2124982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hade</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Spiro</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Calcium and acid rebound: a reappraisal.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-44</page-range>
            <pub-id pub-id-type="pmid">1500660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preclik</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stange</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fetzer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ditschuneit</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effect of antacid treatment on endogenous prostaglandin synthesis in human antral and duodenal mucosa.</article-title>
            <source>Dig Dis Sci</source>
            <year>1989</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>1860</fpage>
            <page-range>1860-4</page-range>
            <pub-id pub-id-type="pmid">2598753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez-Stanley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zubaidi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akbarali</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Mellow</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Calcium carbonate antacids alter esophageal motility in heartburn sufferers.</article-title>
            <source>Dig Dis Sci</source>
            <year>2004</year>
            <season>Nov-Dec</season>
            <volume>49</volume>
            <issue>11-12</issue>
            <fpage>1862</fpage>
            <page-range>1862-7</page-range>
            <pub-id pub-id-type="pmid">15628717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sunyecz</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The use of calcium and vitamin D in the management of osteoporosis.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>827</fpage>
            <page-range>827-36</page-range>
            <pub-id pub-id-type="pmid">19209265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Recker</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Calcium absorption and achlorhydria.</article-title>
            <source>N Engl J Med</source>
            <year>1985</year>
            <month>Jul</month>
            <day>11</day>
            <volume>313</volume>
            <issue>2</issue>
            <fpage>70</fpage>
            <page-range>70-3</page-range>
            <pub-id pub-id-type="pmid">4000241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bua</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Capodice</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A comparative study of calcium absorption following a single serving administration of calcium carbonate powder versus calcium citrate tablets in healthy premenopausal women.</article-title>
            <source>Food Nutr Res</source>
            <year>2014</year>
            <volume>58</volume>
            <pub-id pub-id-type="pmid">24772062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicar</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pak</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Calcium bioavailability from calcium carbonate and calcium citrate.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1985</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>391</fpage>
            <page-range>391-3</page-range>
            <pub-id pub-id-type="pmid">4008614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Hyperphosphatemia Management in Patients with Chronic Kidney Disease.</article-title>
            <source>Saudi Pharm J</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>494</fpage>
            <page-range>494-505</page-range>
            <pub-id pub-id-type="pmid">27330380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harvey</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zobitz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pak</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate.</article-title>
            <source>J Bone Miner Res</source>
            <year>1988</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-8</page-range>
            <pub-id pub-id-type="pmid">3213620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Schnoll-Sussman</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Yadlapati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spechler</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-56</page-range>
            <pub-id pub-id-type="pmid">34807007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <chapter-title>Antacids</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>7</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nykamp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Antacid-induced acute pancreatitis.</article-title>
            <source>Consult Pharm</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>247</fpage>
            <page-range>247-51</page-range>
            <pub-id pub-id-type="pmid">23552706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniel</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Wadman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Branecki</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Milk-alkali-induced pancreatitis in a chronically hypocalcemic patient with DiGeorge syndrome.</article-title>
            <source>J Emerg Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>e63</fpage>
            <page-range>e63-6</page-range>
            <pub-id pub-id-type="pmid">25498850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorensen</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Calcium intake and urinary stone disease.</article-title>
            <source>Transl Androl Urol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-40</page-range>
            <pub-id pub-id-type="pmid">26816771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medarov</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Milk-alkali syndrome.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>261</fpage>
            <page-range>261-7</page-range>
            <pub-id pub-id-type="pmid">19252114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Calcium content of different compositions of gallstones and pathogenesis of calcium carbonate gallstones.</article-title>
            <source>Asian J Surg</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-35</page-range>
            <pub-id pub-id-type="pmid">23270822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herzog</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Holterm&#x000fc;ller</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Antacid therapy--changes in mineral metabolism.</article-title>
            <source>Scand J Gastroenterol Suppl</source>
            <year>1982</year>
            <volume>75</volume>
            <fpage>56</fpage>
            <page-range>56-62</page-range>
            <pub-id pub-id-type="pmid">6293043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatlebakk</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Berstad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>386</fpage>
            <page-range>386-406</page-range>
            <pub-id pub-id-type="pmid">9118586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cook</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dassenko</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Calcium supplementation: effect on iron absorption.</article-title>
            <source>Am J Clin Nutr</source>
            <year>1991</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <page-range>106-11</page-range>
            <pub-id pub-id-type="pmid">1984334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolland</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Grey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Calcium supplements and cardiovascular risk: 5 years on.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>199</fpage>
            <page-range>199-210</page-range>
            <pub-id pub-id-type="pmid">25114781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill Gallant</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Spiegel</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Calcium Balance in Chronic Kidney Disease.</article-title>
            <source>Curr Osteoporos Rep</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <page-range>214-221</page-range>
            <pub-id pub-id-type="pmid">28474258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steadman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Raisch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Esterly</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Postelnick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Trifilio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yarnold</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Scheetz</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a potential clinical interaction between ceftriaxone and calcium.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>1534</fpage>
            <page-range>1534-40</page-range>
            <pub-id pub-id-type="pmid">20086152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31520.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camidge</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peaston</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Recommended dose antacids and severe hypercalcaemia.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-2</page-range>
            <pub-id pub-id-type="pmid">11560570</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
